Concurrent Antidepressant Use and Metastasis Risk Among Women Receiving Tamoxifen for Breast Cancer: A Real‐World Cohort Study
Open Access
- 30 September 2026
- journal article
- Published by Wiley in Psycho-Oncology
- Vol. 35 (10)
Abstract
Objective: Concurrent use of antidepressants, particularly cytochrome P450 2D6 (CYP2D6) inhibitors, may reduce tamoxifen bioactivation and effectiveness. However, the clinical significance of this potential interaction remains inconclusive. This study examined whether concurrent antidepressant use is associated with increased metastasis risk among women receiving tamoxifen for nonmetastatic breast cancer. Methods: We conducted a cohort study using the Merative MarketScan Database. Eligible women with nonmetastatic breast cancer were followed from tamoxifen initiation until metastasis, disenrollment, or study end, whichever occurred first. Patients were classified as concurrent users (tamoxifen with overlapping antidepressant prescriptions) or nonusers (tamoxifen only). Time‐dependent Cox models estimated metastasis risk. Analyses were stratified by concurrent exposure duration and CYP2D6 inhibition degree and adjusted for relevant covariates. Results: Among 14,771 women (mean age: 51 ± 10 years), 4780 (32.4%) used tamoxifen concurrently with an antidepressant, most commonly moderate inhibitors ( n = 1815) and least commonly strong inhibitors ( n = 427). Median overlap duration was 8 months (IQR: 3–20). During follow‐up, 443 patients (3.0%) developed metastasis: 161 of 4780 concurrent users (3.4%) versus 282 of 9991 nonusers (2.8%). Concurrent antidepressant use was not significantly associated with metastasis risk (HR = 0.99; 95% CI: 0.81–1.21). Exposure duration was also not significantly associated with metastasis. Use of mixed‐inhibitor regimens was associated with higher risk in partially adjusted models (HR = 1.39; 95% CI: 1.04–1.87), though full adjustment attenuated the association. Conclusions: Concurrent antidepressant use was not significantly associated with increased metastasis risk among women receiving tamoxifen for nonmetastatic breast cancer. Individualized and coordinated decisions regarding antidepressant selection may help balance cancer control goals with the psychological and symptomatic management needs in this population.Keywords
This publication has 18 references indexed in Scilit:
- Drug Interactions With Tamoxifen and Treatment Effectiveness in Premenopausal Breast Cancer Patients: A Bayesian Joint Modeling ApproachPharmacoepidemiology and Drug Safety, 2025
- Pascal's uncertainty principle: Managing drug–drug interactions when the risks are unclearJACCP: Journal of the American College of Clinical Pharmacy, 2024
- Time to Update Evidence-Based Guideline Recommendations About Concurrent Tamoxifen and Antidepressant Use? A Systematic ReviewClinical Breast Cancer, 2022
- Multigene and Drug Interaction Approach for Tamoxifen Metabolite Patterns Reveals Possible Involvement of CYP2C9, CYP2C19, and ABCB1The Journal of Clinical Pharmacology, 2016
- Tamoxifen and Antidepressant Drug Interaction in a Cohort of 16 887 Breast Cancer SurvivorsJNCI: Journal of the National Cancer Institute, 2015
- Pharmacoepidemiologic Methods for Studying the Health Effects of Drug–Drug InteractionsClinical Pharmacology & Therapeutics, 2015
- CYP2D6 Inhibition and Breast Cancer Recurrence in a Population-Based Study in DenmarkJNCI: Journal of the National Cancer Institute, 2011
- The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studiesJournal of Clinical Epidemiology, 2008
- CYP2D6 Genotype, Antidepressant Use, and Tamoxifen Metabolism During Adjuvant Breast Cancer TreatmentJNCI: Journal of the National Cancer Institute, 2005
- Active Tamoxifen Metabolite Plasma Concentrations After Coadministration of Tamoxifen and the Selective Serotonin Reuptake Inhibitor ParoxetineJNCI: Journal of the National Cancer Institute, 2003